Medtronic plc — Director's Dealing 2021

Aug 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Medtronic plc (MDT)
CIK: 0001613103
Period of Report: 2021-08-02

Reporting Person: Salmon Sean (EVP & Pres Diabetes/Cardiovasc)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-02	Ordinary Shares	F	2272	$131.31	Disposed	27843	Direct
2021-08-02	Ordinary Shares	A	5486	—	Acquired	33329	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-02	Stock Option (Right to Buy)	$131.26	A	46867	Acquired	2031-08-02	Ordinary Shares (46867)	Direct
2021-08-02	Stock Option (Right to Buy)	$131.26	A	1085	Acquired	2031-08-02	Ordinary Shares (1085)	Direct
2021-08-02	Performance Share Units	$	A	13714	Acquired		Performance Share Units (13714)	Direct

Footnotes

F1: This amount has been adjusted to correct a mathematical error in exempt transactions such as dividend reinvestment.

F2: This balance increased by 163 shares due to exempt transactions such as dividend reinvestment.

F3: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date.

F4: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant.

F5: Each performance share unit represents a contingent right to receive one share of Medtronic common stock.

F6: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 13,714 shares will be issued. The actual number of shares to be issued could range from a low of 2,743 at minimum performance to a high of 27,428 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares.

F7: Vests on August 2, 2024.